Loading clinical trials...
Loading clinical trials...
A Phase 1b Open Label, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT-100 in Patients With Duchenne Muscular Dystrophy
Conditions
Interventions
HT-100
Locations
5
United States
University of California, Davis Medical Center
Sacramento, California, United States
Kennedy Krieger Institute, Johns Hopkins School of Medicine
Baltimore, Maryland, United States
Washington University School of Medicine
St Louis, Missouri, United States
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
Nationwide Children's Hospital
Columbus, Ohio, United States
Start Date
May 1, 2013
Primary Completion Date
March 30, 2016
Completion Date
March 30, 2016
Last Updated
September 3, 2020
NCT07037862
NCT07160634
NCT06450639
NCT07129954
NCT06290713
NCT06925269
Lead Sponsor
Processa Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions